Evidence map›Paper›PMID 35293783›Full record

Trial reportAntimicrobial agents and chemotherapy2022

Assessment of Long-Term Macrolide Exposure on the Oropharyngeal Microbiome and Macrolide Resistance in Healthy Adults and Consequences for Onward Transmission of Resistance.

Lucy D Burr, Steven L Taylor, Alyson Richard, Veronika Schreiber, Stevie Lingman, Megan Martin, Lito E Papanicolas, Jocelyn M Choo, Geraint B Rogers

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Lucy D BurrDepartment of Respiratory Medicine, Mater Adult Hospitalgrid.416528.c, South Brisbane, Queensland, Australia.
Steven L TaylorMicrobiome & Host Health Programme, South Australia Health and Medical Research Institute, North Terrace, Adelaide, South Australia, Australia.
Alyson RichardMicrobiome & Host Health Programme, South Australia Health and Medical Research Institute, North Terrace, Adelaide, South Australia, Australia.
Veronika SchreiberImmunity, Infection, and Inflammation Program, Mater Research Institute-University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.
Stevie LingmanDepartment of Respiratory Medicine, Mater Adult Hospitalgrid.416528.c, South Brisbane, Queensland, Australia.
Megan MartinDepartment of Respiratory Medicine, Mater Adult Hospitalgrid.416528.c, South Brisbane, Queensland, Australia.
Lito E PapanicolasInfection and Immunity, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
Jocelyn M Choo *Microbiome & Host Health Programme, South Australia Health and Medical Research Institute, North Terrace, Adelaide, South Australia, Australia.ORCID 0000-0001-9500-8360
Geraint B Rogers *Microbiome & Host Health Programme, South Australia Health and Medical Research Institute, North Terrace, Adelaide, South Australia, Australia.
Flinders University · AUMater Adult Hospital · AUTranslational Research Institute · AUSouth Australian Health and Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the use of long-term macrolide therapy to prevent exacerbations in chronic respiratory diseases is widespread, its impact on the oropharyngeal microbiota and macrolide resistance, and the potential for onward transmission of resistance to close contacts are poorly understood. We determined the effects of long-term exposure to azithromycin or erythromycin on phenotypic and genotypic macrolide resistance within the oropharyngeal microbiome of healthy adults and their close contacts in a randomized, single-blinded, parallel-group trial of 4 weeks of twice-daily oral 400 mg erythromycin ethylsuccinate or twice-daily oral 125 mg azithromycin. Using oropharyngeal swabs collected from 20 index healthy adults and 20 paired close contacts, the oropharyngeal microbial composition and macrolide resistance in streptococci were assessed by 16S rRNA sequencing and antibiotic susceptibility testing of oropharyngeal cultures, respectively, at baseline and weeks 4 and 8 (washout). Targeted quantitative PCR of antibiotic resistance genes was performed to evaluate paired changes in resistance gene levels in index patients and close contacts and to relate the potential transmission of antibiotic resistance. Neither azithromycin nor erythromycin altered oropharyngeal microbiota characteristics significantly. Proportional macrolide resistance in oropharyngeal streptococci increased with both erythromycin and azithromycin, remaining above baseline levels for the azithromycin group at washout. Levels of resistance genes increased significantly with azithromycin[

Indexed as

Anti-Bacterial AgentsMicrobiotaAdultAustraliaAzithromycinDrug Resistance, BacterialErythromycinHumansMacrolidesRNA, Ribosomal, 16SStreptococcusAnti-Bacterial AgentsAzithromycinErythromycinMacrolidesRNA, Ribosomal, 16Santibiotic resistance genesantibiotic resistance transmissionazithromycinerythromycinhealthy adultsmacrolidesoropharyngeal microbiome

Identifiers

PMID35293783
PMCPMC9017296
OpenAlexW4221007527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.